1,720,991 research outputs found
Evidence-based medicine, the number ‘three’ and its multiples in urological clinical rules
No full textCan the success with immunotherapy in metastatic urothelial bladder carcinoma be replicated in the neoadjuvant setting?
No full textFecal microbiota transplantation for immunotherapy-resistant urological tumors: Is it time? An update of the recent literature
No full textAntibodies targeting prostate-specific membrane antigen positive prostate cancer: from diagnostic imaging to theranostics
No full textPurpose of review Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personalized medicine in prostate cancer (PCa) patients. This review aims to highlight the role of PSMA targeting antibodies in PCa, for diagnostic and therapeutic purposes. Recent findings PSMA Positron Emission Tomography/Computed Tomography has been a game changer in the diagnosis of PCa in the recent decade. Two anti-PSMA monoclonal antibodies have been studied in PCa: 7E11-C35 (limited use) and J591. J591 antibody was used for diagnostic purposes coupled with different radionuclides. Most importantly, it was combined to numerous therapeutic radionuclides such as Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Indium-111 (In-111), and Actinium-225 (Ac-225). It was also conjugated to drugs forming antibody-drug conjugates (e.g. MLN2704 and PSMA-ADC). These compounds were tested in recent phase I/II clinical trials. PSMA targeting antibodies are very promising for further clinical investigation and continue to be a momentous research area, for both imaging and therapeutic settings. Although some clinical trials resulted in unfavorably safety profiles for some antibodies, they validated PSMA as a crucial immunoconjugate target
COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor|COVID-19 et la susceptibilité du sexe masculin: le rôle de l'ACE2, la TMPRSS2 et le récepteur aux androgènes
No full textCOVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy. (C) 2020 Elsevier Masson SAS. All rights reserved
Prostate cancer, androgen deprivation, and risk of COVID-19 infection: A systematic review and meta-analysis|Cancer de Prostate, déprivation androgénique, et risques d'infection par la COVID-19: revue systématique et méta-analyse
No full text
Is there a role for repeating PSMA PET/CT after a negative scan in biochemical recurrent prostate cancer?
No full text
Does antibiotic use explain the discrepancy of urolithiasis prevalence between countries?
No full text- …
